GO:0141091 transforming growth factor beta receptor superfamily signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0141091 describes the entire signaling cascade triggered when an extracellular ligand binds a transforming growth factor beta (TGF-beta) receptor superfamily member, culminating in regulation of downstream cellular processes such as transcription.
• The pathway is initiated by ligands including TGF-beta isoforms, activins, inhibins, bone morphogenetic proteins (BMPs), and growth differentiation factors, which assemble receptor complexes and activate Smad-dependent and Smad-independent signaling.
• Core signal transduction relies on type I and type II serine/threonine kinase receptors; ligand binding enables type II receptors to phosphorylate and activate type I receptors, which then phosphorylate receptor-regulated Smads (R-Smads).
• Dysregulation of this pathway is implicated in numerous human diseases, including colorectal cancer, anemia, and fibrotic disorders, making it a major therapeutic target.
• Small-molecule inhibitors such as SB-431542 selectively block ALK4, ALK5, and ALK7, providing chemical tools to dissect pathway-specific functions.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for causal validation of genes in this pathway and for preclinical target discovery.
Description
The transforming growth factor beta (TGF-beta) receptor superfamily signaling pathway (GO:0141091) is a fundamental biological process that converts extracellular cues into changes in gene expression and cell behavior. It is defined by the binding of ligands such as TGF-beta isoforms, activins, and bone morphogenetic proteins (BMPs) to a family of serine/threonine kinase receptors, which then propagate signals to Smad proteins and other downstream effectors. This pathway controls diverse cellular outcomes, including proliferation, differentiation, apoptosis, migration, and extracellular matrix production, and is essential for embryonic development and tissue homeostasis. Because of its broad roles, the pathway is a focal point in cancer, fibrosis, immune regulation, and regenerative medicine research. For example, TGF-beta superfamily signaling is frequently altered in colorectal cancer, where it can shift from a tumor-suppressive to a tumor-promoting role. In hematology, a ligand trap targeting the pathway (ACE-536) corrects anemia by promoting late-stage erythropoiesis, illustrating its therapeutic tractability. Understanding the precise molecular steps, regulatory mechanisms, and disease connections of GO:0141091 is therefore critical for researchers aiming to develop targeted interventions. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of the pathway, its key genes, experimental models, and methods for functional interrogation.
transforming growth factor beta receptor superfamily signaling pathway At A Glance
| GO ID | GO:0141091 |
|---|---|
| GO term | transforming growth factor beta receptor superfamily signaling pathway |
| Ontology | biological_process |
| Synonym | TGF-beta receptor superfamily signaling pathway; TGFbeta receptor superfamily signaling pathway; TGF-beta receptor superfamily signalling pathway; TGFbeta receptor superfamily signalling pathway; transforming growth factor beta receptor superfamily signalling pathway |
| Major function | Transduces extracellular TGF-beta superfamily ligand signals into intracellular responses, including regulation of transcription, proliferation, differentiation, and apoptosis. |
| Ligand examples | TGF-beta isoforms, activins, inhibins, BMPs, growth differentiation factors. |
| Receptor types | Type I and type II serine/threonine kinase receptors (e.g., ALK4, ALK5, ALK7). |
| Key intracellular transducers | Smad proteins (R-Smads, Co-Smad, I-Smads). |
| Disease relevance | Colorectal cancer, anemia, fibrosis, and other disorders. |
What Is GO:0141091?
GO:0141091, transforming growth factor beta receptor superfamily signaling pathway, is defined as the series of molecular signals initiated by an extracellular ligand binding to a member of the transforming growth factor receptor superfamily, and ending with the regulation of a downstream cellular process, e.g. transcription. In simpler terms, it is the entire communication chain that starts when a TGF-beta-like ligand docks onto its receptor on the cell surface and finishes with changes inside the cell, such as turning genes on or off.
Why Is transforming growth factor beta receptor superfamily signaling pathway Important in Cell Biology?
GO:0141091 is critically important because it governs a vast array of cellular decisions and is frequently dysregulated in human disease. The pathway integrates signals from more than 30 ligands and a correspondingly diverse set of receptors, allowing cells to respond to their environment with context-dependent outputs. Its role in cancer is particularly well documented: in colorectal cancer, TGF-beta superfamily signaling can suppress early tumor formation but later promote invasion and metastasis. Moreover, therapeutic agents that modulate the pathway, such as the ligand trap ACE-536, have shown clinical benefit in anemia, demonstrating that precise manipulation of this signaling axis is feasible. Consequently, understanding GO:0141091 is essential for both basic developmental biology and translational medicine.
• Controls fundamental cellular processes including proliferation, differentiation, apoptosis, and migration.
• Central to embryonic development and tissue homeostasis across metazoans.
• Frequently mutated or dysregulated in colorectal cancer and other malignancies.
• Therapeutic targeting can correct anemia by promoting late-stage erythropoiesis.
• Small-molecule inhibitors (e.g., SB-431542) enable selective blockade of ALK4/5/7 for research and drug development.
• Glycosylation of ligands and receptors mutually regulates pathway activity, adding another layer of control.
• Co-receptors modulate ligand-receptor interactions and contribute to signaling specificity in cancer.
• Activin receptor signaling, a sub-branch of this pathway, is a validated target in several diseases.
• CRISPR screens and knockout models are indispensable for identifying causal genes within the pathway.
• The pathway is a rich source of biomarkers and drug targets for fibrosis, cancer, and blood disorders.
What Happens During transforming growth factor beta receptor superfamily signaling pathway?
Ligand Binding and Receptor Complex Assembly
In simple terms: First, a signaling molecule outside the cell attaches to receptor proteins on the cell surface.
The pathway begins when an extracellular ligand from the TGF-beta superfamily, such as TGF-beta, activin, or BMP, binds to a type II serine/threonine kinase receptor on the cell membrane. This binding recruits and assembles a complex with a type I receptor, forming a heteromeric receptor complex. Ligand specificity is determined by the combination of type I and type II receptors; for example, activins signal through ALK4, while TGF-beta uses ALK5. Co-receptors such as betaglycan and endoglin can further modulate ligand presentation and receptor activation.
Receptor Activation and Smad Phosphorylation
In simple terms: The receptor complex becomes active and tags downstream proteins with phosphate groups to pass the signal inward.
Upon complex formation, the constitutively active type II receptor kinase phosphorylates the type I receptor in its GS domain, thereby activating the type I receptor kinase. The activated type I receptor then phosphorylates receptor-regulated Smads (R-Smads) such as Smad2 and Smad3 (for TGF-beta/activin branches) or Smad1, Smad5, and Smad8 (for BMP branches) at their C-terminal SSXS motif. This phosphorylation is a critical step that licenses R-Smads to form complexes with the common mediator Smad4.
Smad Complex Translocation and Transcriptional Regulation
In simple terms: The tagged proteins move into the nucleus and switch genes on or off.
Phosphorylated R-Smads associate with Smad4 and translocate into the nucleus, where they bind DNA directly or via other transcription factors to regulate target gene expression. This transcriptional output determines the cellular response, which can include cell cycle arrest, differentiation, apoptosis, or epithelial-mesenchymal transition depending on context. Inhibitory Smads (I-Smads), such as Smad6 and Smad7, provide negative feedback by interfering with receptor-Smad interactions or promoting receptor degradation.
Non-Smad Signaling Branches
In simple terms: The pathway can also activate other cellular switches besides Smads.
In addition to Smad-mediated signaling, TGF-beta superfamily receptors can activate non-Smad pathways, including MAPK, PI3K-AKT, and Rho-like GTPase signaling. These branches contribute to diverse biological outcomes and can crosstalk with Smad signaling. For instance, TGF-beta-activated kinase 1 (TAK1) is a key mediator of non-Smad signaling downstream of the receptors. The balance between Smad and non-Smad signaling influences the overall cellular response and is often altered in disease.
Regulation by Glycosylation and Co-receptors
In simple terms: Sugar modifications and helper proteins fine-tune the signal.
Glycosylation of TGF-beta isoforms and their receptors can mutually regulate pathway activity, affecting ligand secretion, receptor affinity, and downstream signaling strength. Co-receptors such as betaglycan and endoglin modulate ligand access to signaling receptors and can enhance or inhibit specific branches. These regulatory layers ensure that the pathway responds appropriately to developmental and homeostatic cues, and their disruption contributes to disease.
Key Genes Involved in GO:0141091 transforming growth factor beta receptor superfamily signaling pathway
The following genes encode core components and regulators of the transforming growth factor beta receptor superfamily signaling pathway (GO:0141091), with established roles in signal transduction, modulation, and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Encodes TGF-beta 1, a prototypic ligand that initiates signaling through TGF-beta receptors. | Widely studied in fibrosis, cancer, and immune regulation; frequent target for knockout and overexpression models. |
| TGFBR1 | Encodes TGF-beta receptor type I (ALK5), a serine/threonine kinase that phosphorylates R-Smads. | Key node for small-molecule inhibition (e.g., SB-431542) and CRISPR knockout to dissect canonical signaling. |
| TGFBR2 | Encodes TGF-beta receptor type II, which binds ligand and activates type I receptors. | Frequently mutated in colorectal cancer; knockout models reveal tumor-suppressive functions. |
| ACVR1B | Encodes activin receptor type IB (ALK4), mediating activin signaling. | Target for understanding activin-specific outcomes; inhibitor SB-431542 blocks ALK4. |
| ACVR1C | Encodes activin receptor type IC (ALK7), involved in metabolic and reproductive signaling. | Less studied; CRISPR models can uncover tissue-specific roles. |
| SMAD2 | Encodes a receptor-regulated Smad that transmits TGF-beta/activin signals. | Essential for transcriptional responses; knockout causes embryonic lethality in mice. |
| SMAD3 | Encodes a receptor-regulated Smad mediating TGF-beta/activin signals. | Linked to fibrosis and cancer; point mutations used to study phosphorylation-dependent functions. |
| SMAD4 | Encodes the common mediator Smad (Co-Smad) required for canonical signaling. | Frequently inactivated in pancreatic and colorectal cancers; knockout models show loss of TGF-beta responses. |
| SMAD1 | Encodes a BMP-specific R-Smad. | Important for bone and developmental studies; knockout affects BMP signaling. |
| SMAD5 | Encodes a BMP-specific R-Smad. | Participates in BMP-induced differentiation; used in knock-in reporter models. |
| SMAD6 | Encodes an inhibitory Smad that negatively regulates BMP signaling. | Overexpression studies reveal feedback control; knockout can enhance BMP responses. |
| SMAD7 | Encodes an inhibitory Smad that blocks TGF-beta/activin signaling. | Induced by TGF-beta as negative feedback; knockout mice show enhanced fibrosis. |
| BMP2 | Encodes bone morphogenetic protein 2, a ligand in the BMP branch. | Critical for osteogenesis; used in differentiation protocols and knockout models. |
| BMP4 | Encodes bone morphogenetic protein 4, a ligand regulating development. | Studied in stem cell differentiation and cancer; overexpression models available. |
| INHBA | Encodes inhibin beta A subunit, forming activin A. | Regulates erythropoiesis and reproduction; ligand trap ACE-536 targets this axis. |
| ENG | Encodes endoglin, a co-receptor for TGF-beta superfamily ligands. | Mutated in hereditary hemorrhagic telangiectasia; knockout models show vascular defects. |
| TGFBR3 | Encodes betaglycan, a co-receptor that modulates ligand access. | Affects TGF-beta bioavailability; knockout alters cancer cell responses. |
| FKBP1A | Encodes FKBP12, which binds and stabilizes type I receptors. | Regulates receptor activation; used in chemical genetics studies. |
How Is transforming growth factor beta receptor superfamily signaling pathway Regulated?
The transforming growth factor beta receptor superfamily signaling pathway is tightly regulated at multiple levels. Extracellularly, ligand availability is controlled by sequestration proteins (e.g., latency-associated peptide, decorin) and co-receptors such as betaglycan and endoglin. At the receptor level, inhibitory Smads (Smad6, Smad7) provide negative feedback by competing with R-Smads for receptor binding or by recruiting ubiquitin ligases to degrade receptors. Intracellularly, phosphorylation and ubiquitination of Smads modulate their stability and activity, and phosphatases can reverse receptor-mediated phosphorylation. Crosstalk with other pathways, including MAPK and PI3K-AKT, fine-tunes the output. Additionally, glycosylation of ligands and receptors adds another regulatory layer that can affect signaling strength and specificity.
transforming growth factor beta receptor superfamily signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR2 | Colorectal cancer, tumor suppression | Knockout in HCT116 or organoid models to assess proliferation and invasion |
| SMAD4 | Colorectal and pancreatic cancer | Point mutation knock-in to mimic patient mutations; xenograft studies |
| INHBA | Anemia, ineffective erythropoiesis | Overexpression and ligand trap (ACE-536) treatment in erythroid cultures |
| ENG | Hereditary hemorrhagic telangiectasia | Knockout endothelial cells to study angiogenesis and vascular permeability |
| TGFB1 | Fibrosis (lung, liver, kidney) | Overexpression in fibroblasts or conditional knockout in mice to assess matrix deposition |
Colorectal Cancer
Dysregulation of TGF-beta superfamily signaling is a hallmark of colorectal cancer (CRC). In early stages, the pathway acts as a tumor suppressor by inhibiting proliferation and inducing apoptosis; however, during tumor progression, cancer cells often become resistant to growth inhibition and the pathway instead promotes epithelial-mesenchymal transition, invasion, and metastasis. Mutations in TGFBR2 and SMAD4 are common in CRC, and loss of SMAD4 correlates with poor prognosis. Targeting the pathway in CRC requires careful consideration of context-dependent effects.
Anemia and Hematological Disorders
The TGF-beta superfamily ligand trap ACE-536 (luspatercept) corrects anemia by promoting late-stage erythropoiesis. This therapeutic success highlights the importance of activin receptor signaling, a branch of GO:0141091, in red blood cell development. By sequestering ligands such as activin A and GDF11, ACE-536 relieves Smad2/3-mediated inhibition of erythroid maturation, offering a targeted approach for beta-thalassemia and myelodysplastic syndromes.
Fibrotic Diseases
TGF-beta is a master driver of fibrosis in multiple organs, including lung, liver, and kidney. Excessive TGF-beta signaling promotes myofibroblast activation and extracellular matrix deposition, leading to tissue scarring and organ failure. Inhibitors of ALK5 (e.g., SB-431542) and Smad3 knockout models have been used to attenuate fibrosis in preclinical studies. The pathway is therefore a prime target for antifibrotic drug development.
Developmental Disorders and Vascular Malformations
Mutations in components of the pathway, such as ENG (endoglin) and ACVRL1 (ALK1), cause hereditary hemorrhagic telangiectasia, characterized by vascular malformations. BMP signaling is also critical for skeletal development; disruptions lead to bone disorders. These examples underscore the pathway's essential roles in development and tissue homeostasis.
From transforming growth factor beta receptor superfamily signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFBR2 alter proliferation in colorectal cancer cells? | CRISPR knockout of TGFBR2 in HCT116 or patient-derived organoids |
| How does a specific SMAD3 phosphorylation site affect transcriptional output? | Point mutation knock-in of SMAD3 (e.g., phospho-null) in HEK293 or cancer cell lines |
| Can a reporter gene track TGF-beta pathway activity in real time? | Knock-in of a luciferase or fluorescent reporter downstream of a Smad-binding element |
| What is the effect of SMAD7 overexpression on fibrosis? | Overexpression of SMAD7 in hepatic stellate cells or transgenic mice |
| Which genes are essential for activin-mediated erythropoiesis? | CRISPR library screening in erythroid progenitor cells |
| How does endoglin modulate BMP signaling in endothelial cells? | Knockout and tagged knock-in of ENG in HUVECs followed by proteomics |
How to Study the transforming growth factor beta receptor superfamily signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global changes in mRNA levels | Identify transcriptional targets of TGF-beta/activin/BMP signaling |
| Phosphoproteomics | Phosphorylation events on Smads and other proteins | Map receptor kinase substrates and signaling dynamics |
| Smad nuclear translocation imaging | Subcellular localization of Smad proteins | Assess pathway activation kinetics in live cells |
| CRISPR knockout screens | Gene essentiality or modifiers of pathway activity | Discover novel regulators of TGF-beta superfamily signaling |
| Co-immunoprecipitation + mass spectrometry | Protein-protein interactions | Identify Smad complex components and co-factors |
| Luciferase reporter assays | Transcriptional activity of Smad-responsive elements | Quantify pathway activity in response to ligands or inhibitors |
| Flow cytometry | Cell surface receptor expression and phospho-Smad levels | Analyze pathway activation in heterogeneous cell populations |
| Organoid culture | Three-dimensional tissue-like responses | Model colorectal cancer and test pathway-targeted drugs |
Transcriptomic Profiling (RNA-seq)
RNA sequencing is widely used to measure global changes in gene expression upon activation or inhibition of the TGF-beta superfamily pathway. For example, treating cells with SB-431542, a selective inhibitor of ALK4/5/7, followed by RNA-seq can reveal pathway-dependent transcriptional programs. This method helps identify downstream targets and feedback regulators such as SMAD7.
Proteomic Analysis of Smad Complexes
Affinity purification coupled with mass spectrometry can identify proteins that associate with Smad complexes upon ligand stimulation. This approach has been used to uncover co-factors and non-Smad interactors that modulate signaling. Phosphoproteomics can also quantify receptor-mediated phosphorylation events on Smads and other substrates.
Imaging of Smad Nuclear Translocation
Fluorescence microscopy of GFP-tagged Smads allows real-time visualization of nuclear translocation following ligand addition. This technique provides spatial and temporal information about pathway activation and can be adapted for high-content screening. It is particularly useful for studying the kinetics of Smad2/3 versus Smad1/5/8 responses.
CRISPR Screens for Pathway Modifiers
Genome-wide CRISPR knockout or activation screens can identify genes that regulate TGF-beta superfamily signaling. For instance, a screen for modifiers of BMP-induced differentiation may uncover novel co-receptors or intracellular regulators. Such screens are powerful for discovering new therapeutic targets within the pathway.
How CRISPR Can Be Used to Study GO:0141091 transforming growth factor beta receptor superfamily signaling pathway
Knockout
CRISPR knockout of core pathway genes such as TGFBR2, SMAD4, or SMAD2/3 is widely used to ablate signaling and assess downstream phenotypes. For example, TGFBR2 knockout in colorectal cancer cell lines abolishes TGF-beta-induced growth inhibition, mimicking patient mutations. Knockout models are also valuable for validating off-target effects of pharmacological inhibitors.
Point Mutation
Point mutations can be introduced to study specific phosphorylation sites or disease-associated variants. For instance, knocking in a phospho-null mutation in SMAD3 (e.g., T179A) can reveal the contribution of that residue to transcriptional regulation. Such models are essential for understanding how subtle genetic changes alter pathway output.
Knock-in
Knock-in of reporter genes (e.g., luciferase or fluorescent proteins) under the control of Smad-responsive promoters allows real-time monitoring of pathway activity. Alternatively, epitope tags can be knocked into endogenous loci to study protein interactions and localization. These models facilitate high-throughput screening and dynamic studies.
Overexpression
Overexpression of ligands (e.g., TGFB1), receptors, or inhibitory Smads (e.g., SMAD7) can amplify or dampen signaling. For example, SMAD7 overexpression is used to block TGF-beta-induced fibrosis in cell and animal models. Overexpression models help establish sufficiency and are complementary to loss-of-function approaches.
How EDITGENE Supports transforming growth factor beta receptor superfamily signaling pathway Research
Researchers studying transforming growth factor beta receptor superfamily signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway regulation or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and accelerating therapeutic discovery.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta receptor superfamily signaling pathway research.
Frequently Asked Questions About transforming growth factor beta receptor superfamily signaling pathway
What is GO:0141091?
GO:0141091 is the Gene Ontology term for the transforming growth factor beta receptor superfamily signaling pathway, defined as the series of molecular signals initiated by an extracellular ligand binding to a member of the TGF-beta receptor superfamily and ending with regulation of a downstream cellular process, such as transcription.
What genes are involved in the transforming growth factor beta receptor superfamily signaling pathway?
Key genes include ligands (TGFB1, BMP2, INHBA), receptors (TGFBR1, TGFBR2, ACVR1B, ACVR1C), Smads (SMAD2, SMAD3, SMAD4, SMAD1, SMAD5, SMAD6, SMAD7), and co-receptors (ENG, TGFBR3).
How is the TGF-beta receptor superfamily signaling pathway activated?
It is activated when a ligand such as TGF-beta, activin, or BMP binds to a type II receptor, which then recruits and phosphorylates a type I receptor, leading to Smad phosphorylation and transcriptional regulation.
What are the downstream effects of TGF-beta superfamily signaling?
Downstream effects include regulation of cell proliferation, differentiation, apoptosis, migration, extracellular matrix production, and immune responses, depending on cell context.
Which diseases are associated with dysregulation of this pathway?
Dysregulation is linked to colorectal cancer, anemia, fibrosis, hereditary hemorrhagic telangiectasia, and various developmental disorders.
What inhibitors are available for studying this pathway?
SB-431542 is a potent and specific inhibitor of ALK4, ALK5, and ALK7, commonly used to block TGF-beta/activin signaling in research.
How can CRISPR be used to study the TGF-beta superfamily pathway?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal interrogation of genes in the pathway, from ligand-receptor interactions to Smad-mediated transcription.
What is the role of Smad proteins in this pathway?
Smad proteins are intracellular transducers: R-Smads (Smad2/3 or Smad1/5/8) are phosphorylated by type I receptors, form complexes with Smad4, and translocate to the nucleus to regulate transcription.
How is the pathway regulated by glycosylation?
Glycosylation of TGF-beta isoforms and their receptors can mutually regulate signaling activity, affecting ligand secretion, receptor binding, and downstream responses.
What experimental models are suitable for studying this pathway?
Common models include CRISPR-engineered cell lines, organoids, and animal models with conditional knockouts or knock-ins of pathway genes.
Conclusion
The transforming growth factor beta receptor superfamily signaling pathway (GO:0141091) is a master regulator of cellular behavior, with profound implications for development, homeostasis, and disease. Its complexity, spanning multiple ligands, receptors, Smads, and non-Smad branches, demands precise experimental tools to dissect causal mechanisms. CRISPR-based models, combined with transcriptomics, proteomics, and imaging, offer a robust framework for such studies. As therapeutic targeting of this pathway advances, understanding its context-dependent roles will be key to developing safe and effective interventions.
References
- 1. Lodberg A. 2021. Principles of the activin receptor signaling pathway and its inhibition.. Cytokine Growth Factor Rev 60:1-17 PMID: 33933900
- 2. Inman GJ et al.. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.. Mol Pharmacol 62(1):65-74 PMID: 12065756
- 3. Suragani RN et al.. 2014. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.. Nat Med 20(4):408-14 PMID: 24658078
- 4. Chen Z et al.. 2023. Mutual regulation between glycosylation and transforming growth factor-β isoforms signaling pathway.. Int J Biol Macromol 236:123818 PMID: 36858092
- 5. Jung B et al.. 2017. Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.. Gastroenterology 152(1):36-52 PMID: 27773809
- 6. Wrana JL. 2000. Crossing Smads.. Sci STKE 2000(23):re1 PMID: 11752591
- 7. Pawlak JB et al.. 2022. TGF-β superfamily co-receptors in cancer.. Dev Dyn 251(1):137-163 PMID: 33797167
- 8. Hartsough MT et al.. 1997. Transforming growth factor-beta signaling in epithelial cells.. Pharmacol Ther 75(1):21-41 PMID: 9364579
